MktsMarkets

Precigen, Inc.
NASDAQ: PGENKey statistics
PGEN News
Stories mentioning PGEN from around the web — every one is an open thread, so give it a like or add your take.
Loading news…
Financial statements
As filed, straight from the 10-Q — up to 19 years of history, free, with every line item chartable.
| Line item | Q1 '26Mar 31 | Q4 '25Dec 31 | Q3 '25Sep 30 | Q2 '25Jun 30 | Q1 '25Mar 31 | Q4 '24Dec 31 | Q3 '24Sep 30 | Q2 '24Jun 30 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 23,252 | 1,341 | ||||||
| Cost of Goods Sold | ||||||||
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | ||||
| Operating Expenses | ||||||||
| Research & Development | 5,638 | 10,478 | ||||||
| Sales General & Admin | 21,049 | 12,359 | ||||||
| Total Operating Expenses | 29,246 | 23,937 | ||||||
| Operating Income (Loss) | (5,994) | (22,596) | ||||||
| Interest Income | ||||||||
| Interest Expense | ||||||||
| Other Expense | 290.00 | 7.00 | ||||||
| Pretax Income | (7,929) | (54,153) | (19,814) | (23,966) | (60,481) | |||
| Tax Provision | 0.00 | 0.00 | 0.00 | 3.00 | 0.00 | (87.00) | 12.00 | (1,689) |
| Net Income (Loss) | (7,929) | (23,503) | (146,344) | (26,642) | (54,153) | (19,727) | (23,978) | (58,792) |
| Earnings Per Share (Basic) | (0.02) | (0.08) | (1.06) | (0.09) | (0.18) | (0.07) | (0.09) | (0.23) |
| Earnings Per Share (Diluted) | (0.02) | (0.08) | (1.06) | (0.09) | (0.18) | (0.07) | (0.09) | (0.23) |
| Weighted Average Shares Outstanding (Basic) | 354,291 | 312,981 | 307,170 | 296,435 | 293,880 | 267,727 | 275,881 | 252,367 |
| Weighted Average Shares Outstanding (Diluted) | 354,291 | 312,981 | 307,170 | 296,435 | 293,880 | 267,727 | 275,881 | 252,367 |
Scroll the table sideways for older periods — the line-item column and the period header stay put. Hover a row and use the chart handle to plot it over the full history.
About PGEN
Precigen, Inc. (NASDAQ: PGEN) is a stock listed on the Nasdaq Stock Market under the ticker symbol PGEN. It last traded at $4.73 (Nov 9, 2026, 9:30 AM ET), up 5.8% on the day. That gives Precigen a market capitalisation of $2.9B.
Over the past 52 weeks PGEN has traded between $3.04 and $8.98.
Revenue for the quarter ended Mar 31, 2026 was $23.3M; a net loss of $7.9M. Revenue was up 1634% from $1.3M in the quarter ended Mar 31, 2025.
| Quarter ended | Revenue | Net income | Margin |
|---|---|---|---|
| Mar 31, 2026 | $23.3M | -$7.9M | -34.1% |
| Dec 31, 2025 | — | -$23.5M | — |
| Sep 30, 2025 | — | -$146.3M | — |
| Jun 30, 2025 | — | -$26.6M | — |
From Precigen’s quarterly (10-Q) filings, in US dollars.
Take a break — play a market game
Seven free games built around the markets. No download, no sign-up: they run right here in your browser.
Latest News
Market news from around the web — every story is an open thread, so give it a like or add your take.
Loading news…